Micronized API represents 61.2% of form demand and ≥99.5% accounts for 67.4% of purity grade sales in 2026. The rivaroxaban market was valued at USD 93.08 million in 2025, is projected to reach USD 107.64 million by 2036 and is forecast to post a 1.09% CAGR between 2026 and 2036.